Executive Management

Tim Van Hauwermeiren co-founded argenx and has served as Chief Executive Officer since April 2008. He has been a member of the Board of Directors since July 2014.

Tim has more than 20 years of general management and business development experience across the life sciences and consumer goods sectors, including at Ablynx and Procter & Gamble. He holds a B.Sc. and M.Sc. in bioengineering from Ghent University and an Executive MBA from The Vlerick School of Management. 

Tim serves on the Board of Directors of iTeos Pharmaceuticals Inc and Lexeo Therapeutics, Inc. .

Key Terms of Contract

Karen Massey joined argenx as Chief Operating Officer in March 2023. Ms. Massey has over 20 years of experience in the biopharma industry, including in commercial leadership, product development, corporate strategy and innovation roles.

Prior to joining argenx, Ms. Massey was with Genentech (Roche Group) for over nine years, where she most recently served as senior vice president of product development and global clinical operations. She previously held various commercial leadership roles across marketing and business operations, including as the vice president of the multiple sclerosis and neuromyelitis optica business.

Ms. Massey started her biopharmaceutical career in marketing at Pfizer and returned there, after two years as a management consultant at Bain & Company, to take on leadership positions in corporate strategy, sales and as a commercial lead in Latin America. Ms. Massey holds a Bachelor of Economics from the University of Sydney and an MBA from the NYU Stern School of Business.

Karl Gubitz joined argenx as Chief Financial Officer in June 2021. Karl worked at Pfizer for nearly 20 years, most recently as Vice President of Finance within the Global Oncology business. During his tenure at Pfizer, he successfully negotiated the commercialization model for tanezumab with Eli Lilly in all non-US markets as well as the Myovant co-commercialization agreement for Orgovyx™.

Within Pfizer, Karl held country, regional, and global positions, and consistently delivered top-line growth. He managed teams of over 250 colleagues in financial leadership roles within the Global Internal Medicine and Global Innovative Products businesses. Prior to joining Pfizer in 2003, Karl held various management roles at PricewaterhouseCoopers.

He holds an M.B.A. from Henley Management College in the UK, Bachelor’s degree in computing from the University of South Africa, and Bachelor of Commerce from the University of Pretoria.

Peter Ulrichts is the Chief Scientific Officer at argenx and joined the company in 2010. In this role, he oversees the development of all clinical and pre-clinical compounds within argenx’s pipeline.

Peter joined the company as a research scientist where he was involved in the development of various therapeutic antibodies for the treatment of cancer and autoimmune diseases. While at argenx, he headed the development of argenx’ FcRn antagonist efgartigimod until the first-in-human study, after which he transitioned to become the lead scientist of the efgartigimod program.

Peter holds a B.S. in Chemistry from KU Leuven as well as an M.S. in Biotechnology and Ph.D. in Immunology, both from the University of Ghent (Belgium).

Malini Moorthy joined argenx as General Counsel in 2022. She has extensive global legal and compliance experience in the pharmaceutical and medical device industries and is a devoted leader known for building, developing, and mentoring high-performing and inclusive teams. Malini was most recently Senior Vice President & Chief Deputy General Counsel, Legal, Compliance & Government Affairs at Medtronic where she played a pivotal role in shaping and driving enterprise and functional strategies. In addition, she served as the Legal Leader supporting the Neuroscience Portfolio, and directly managed Litigation & Investigations, IP Litigation, Employment and Immigration Law, Enterprise Legal Regulatory and Legal Operations.

Before joining Medtronic in 2018, Malini spent four years at Bayer where she was the Head of Global Litigation & Investigations. Prior to that, she progressed in her ten-year career at Pfizer to lead civil litigation globally. Malini began her career as a law firm associate, first with McCarthy Tétrault and Genest Murray Desbrisay Lamek in Toronto, Canada and then Salans (now Dentons) in New York City.

Malini is a graduate of the University of North Carolina at Chapel Hill and the Faculty of Law at Queen’s University in Canada. She is a member of the American Law Institute and serves on the board of Lawyers for Civil Justice and the Leadership Council of the Bolch Judicial Institute at Duke Law School.

Luc Truyen is the Chief Medical Officer of argenx and joined the company in 2021. Previously, Luc was with the Johnson & Johnson organization for over 20 years holding various leadership positions, primarily within neuroscience. He has a strong track record in clinical development resulting in several global innovative drug approvals.

In his most recent position, Luc was global head of development for neuroscience at JNJ and managed the strategy and delivery of the early and late portfolio of assets for mood disorders and schizophrenia, and neurodegenerative and neuroinflammatory disorders.

His broad-based experience also includes leading global clinical development operations for the whole JNJ pharmaceutical group as well as serving as Head of R&D and CMO of Janssen Alzheimer Immunotherapy (JAI), an internal spin-out from JNJ.  Luc holds an M.D. and Ph.D. in Neurology from the University of Antwerp.

Arjen Lemmen serves as Vice President of Corporate Development & Strategy at argenx, which he joined in 2016. In his role, he has successfully executed several transactions including a number of programs within the Immunology Innovation Program and the strategic collaboration with Janssen for cusatuzumab.

Prior to joining argenx, Arjen served as a corporate finance specialist at Kempen & Co focusing on M&A, Equity Capital Markets and strategic advisory transactions in the European life sciences industry. He holds a B.Sc. in Life Science & Technology from the University of Groningen and a Master of Engineering Management from Duke University.

Andria Wilk joined argenx as Global Head of Quality Assurance (QA) in January 2020. She has more than 20 years of experience in QA within the pharmaceutical industry. Most recently, Andria served as Senior Director, Head of Medical, Regulatory & Clinical QA (MRC QA) at Lundbeck, where she managed the global MRC QA group based in the EU, US and Asia.

In this role, she was responsible for the global audit programmes and QA support for all clinical trial and post-marketing activities and related computerized systems. Prior to Lundbeck, she held various QA positions of increasing responsibility within AstraZeneca, Takeda Global Research and Development (TGRD) and Astellas Pharmaceuticals.

Andria holds a joint B.Sc. in Pharmacology and Biochemistry and is a member of Research Quality Association (MRQA).

Marc Schorpion joined argenx as Global Head of Human Resources in December 2018. Marc spent his 35-year career with Johnson & Johnson, most recently as Vice President, Human Resources. In this role, he had global responsibility for talent management and leadership support covering all R&D and Science-based Innovation organizations across Johnson & Johnson. From 2003-2013, Marc led worldwide Human Resources for the Johnson & Johnson Pharmaceuticals Group.

He started his career with Johnson & Johnson in 1983 at Janssen Pharmaceutica in Belgium.  He holds a Licentiate degree in Applied Economics and a Master of Business Administration from the University of Antwerp. In 2019 Marc co-founded United Support for Mothers and Children of India (USMCI), a U.S.-based not-for-profit organization. Marc also serves on the Board of Directors of IGNITE Growth Bands and International School Services (ISS).

Beth DelGiacco is the Vice President, Corporate Communications & Investor Relations at argenx and joined the company in 2018. In this role, Beth is responsible for implementing and executing all internal and external communications strategies to our key stakeholders.

Prior to joining argenx, Beth was a Vice President at Stern Investor Relations, an investor relations firm offering biotechnology companies strategic and client-specific advisory services. She has worked in managing institutional investor relationships for over 15 years, previously on the healthcare team at Guidepoint Global and the Neurology team at Global Data. She holds a Master’s degree in Public Health from Columbia University and a Bachelor’s degree in Chemistry and Spanish from the University of Rochester. She also completed a post-baccalaureate fellowship at the National Institutes of Health.

Filip Borgions is Vice President, Global Head of Technical Operations at argenx and joined the company in 2015. In this role, Filip leads global CMC development, clinical and commercial manufacturing, supply chain and logistics. He has played a pivotal role in the path to approval and launch of the Company’s first commercial product VYVGART and the development of the robust pipeline of product candidates.

Previously, Filip worked in roles of increasing responsibility within CMC at Thrombogenics where he played a crucial role in the global development and commercial launch of Jetrea. He started his industry career at Schering-Plough, currently MSD, in the global CMC and regulatory team. He holds a Ph.D. in Medicinal Chemistry from the Rega Institute at University of Leuven and a Pharmacy degree and a Postgraduate in Business Economics also from University of Leuven.